Allergan Inc. et al. v. Canada (Minister of Health) et al., (2012) 414 F.T.R. 56 (FC)

This document cites

• US Code - 35 U.S.C. § 102 Conditions For Patentability; Novelty
• US Code - 35 U.S.C. § 103 Conditions For Patentability; Non-Obvious Subject Matter
• Eli Lilly Canada Inc. v. Apotex Inc. et al., 2009 FC 320
• Sanofi-Synthelabo Canada Inc. et al. v. Apotex Inc. et al., (2008) 381 N.R. 125 (SCC)
• Pfizer Canada Inc. et al. v. Novopharm Ltd. et al., (2009) 352 F.T.R. 35 (FC)



See all quotations

• Eli Lilly Canada Inc. v. Apotex Inc. et al., (2008) 323 F.T.R. 56 (FC)
• Toronto (City) v. Canadian Union of Public Employees, Local 79 et al., (2003) 179 O.A.C. 291 (SCC)
• Whirlpool Corp. et al. v. Camco Inc. et al., (2000) 263 N.R. 88 (SCC)
• Rothmans, Benson & Hedges Inc. et al. v. Imperial Tobacco Ltd., (1993) 152 N.R. 292 (FCA)
• Pfizer Canada Inc. et al. v. Canada (Minister of Health) et al., 2008 FC 11
• Pfizer Canada Inc. et al. v. Apotex Inc. et al., (2007) 319 F.T.R. 48 (FC)
• Toronto (City) v. Canadian Union of Public Employees, Local 79 et al., (2003) 311 N.R. 201 (SCC)
• Sanofi-Aventis Canada Inc. v. Novopharm Ltd. et al., (2007) 364 N.R. 325 (FCA)
• GlaxoSmithKline Inc. et al. v. Pharmascience Inc. et al., (2011) 385 F.T.R. 157 (FC)
• Janssen-Ortho Inc. et al. v. Apotex Inc. et al., (2009) 392 N.R. 71 (FCA)
• Janssen-Ortho Inc. et al. v. Novopharm Ltd., 2007 FCA 217
• Merck & Co. et al. v. Canada (Minister of Health) et al., 2010 FC 1042
• Shire Biochem Inc. et al. v. Canada (Minister of Health) et al., (2008) 328 F.T.R. 123 (FC)
• Merck & Co. et al. v. Apotex Inc., 2006 FCA 323
• Pfizer Canada Inc. et al. v. Apotex Inc. et al., 2007 FC 26
• Laboratoires Servier et al. v. Apotex Inc. et al., (2009) 392 N.R. 96 (FCA)
• Pfizer Canada Inc. et al. v. Novopharm Ltd. et al., (2010) 408 N.R. 166 (FCA)
• Apotex Inc. v. Pfizer Ireland Pharmaceuticals, 2011 FCA 77
• Glaxo Group Ltd. et al. v. Canada (Minister of National Health and Welfare) et al., (1995) 103 F.T.R. 1 (TD)
• Eli Lilly Canada Inc. v. Novopharm Ltd. et al., [2007] F.T.R. Uned. 828 (FC)
• Allergan Inc. et al. v. Canada (Minister of Health) et al., (2011) 400 F.T.R. 164 (FC)
• Novo Nordisk Canada Inc. et al. v. Cobalt Pharmaceuticals Inc. et al., 2010 FC 746
• Apotex Inc. and Novopharm Ltd. v. Wellcome Foundation Ltd., (2002) 296 N.R. 130 (SCC)
• Pfizer Canada Inc. et al. v. Canada (Minister of Health) et al., 2008 FC 500
• Consolboard Inc. v. MacMillan Bloedel (Saskatchewan) Ltd., (1981) 35 N.R. 390 (SCC)
• Pfizer Canada Inc. et al. v. Canada (Minister of Health) et al., 2007 FC 446
• Pfizer Canada Inc. et al. v. Canada (Minister of Health) et al., (2009) 354 F.T.R. 280 (FC)
• Eli Lilly Canada Inc. et al. v. Novopharm Ltd., (2010) 405 N.R. 1 (FCA)
• Merck & Co. et al. v. Pharmascience Inc. et al., (2010) 368 F.T.R. 1 (FC)
• Pfizer Canada Inc. et al. v. Apotex Inc. et al., 2007 FCA 195